Advertisement
Advertisement
KZIA
Kazia Therapeutics Limited - ADR
5.78
USDSponsored
+0.16
+2.78%
Feb 06, 16:00 UTC -5
Closed
After-Market
5.79
+0.01
+0.24%
KZIA Earnings Reports
Positive Surprise Ratio
KZIA beat 2 of 5 last estimates.
40%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Kazia Therapeutics Limited - ADR earnings per share and revenue
On Nov 07, 2025, KZIA reported earnings of 1.42 USD per share (EPS) for Q4 25, beating the estimate of -1.32 USD, resulting in a 207.09% surprise. Revenue reached 42.00 thousand, compared to an expected 8.16 thousand, with a 414.71% difference. The market reacted with a +0.82% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were Kazia Therapeutics Limited - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Kazia Therapeutics Limited - ADR reported EPS of $1.42, beating estimates by 207.09%, and revenue of $42.00K, 414.71% above expectations.
How did the market react to Kazia Therapeutics Limited - ADR's Q4 2025 earnings?
The stock price moved up 0.82%, changed from $7.33 before the earnings release to $7.39 the day after.
When is Kazia Therapeutics Limited - ADR expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Kazia Therapeutics Limited - ADR's next earnings report?
Based on --
analysts, Kazia Therapeutics Limited - ADR is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement